Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Diabetologia
Erschienen in: Diabetologia 9/2005

01.09.2005 | Review

The metabolic syndrome: time for a critical appraisal

Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

verfasst von: R. Kahn, J. Buse, E. Ferrannini, M. Stern

Erschienen in: Diabetologia | Ausgabe 9/2005

Einloggen, um Zugang zu erhalten

Abstract

Background

The term ‘metabolic syndrome’ refers to a clustering of specific cardiovascular disease (CVD) risk factors whose underlying pathophysiology is thought to be related to insulin resistance.

Methods

Since the term is widely used in research and clinical practice, we undertook an extensive review of the literature in relation to the syndrome’s definition, underlying pathogenesis, association with cardiovascular disease and to the goals and impact of treatment.

Discussion

While there is no question that certain CVD risk factors are prone to cluster, we found that the metabolic syndrome has been imprecisely defined, there is a lack of certainty regarding its pathogenesis, and there is considerable doubt regarding its value as a CVD risk marker. Our analysis indicates that too much critically important information is missing to warrant its designation as a ‘syndrome’.

Conclusion

Until much-needed research is completed, clinicians should evaluate and treat all CVD risk factors without regard to whether a patient meets the criteria for diagnosis of the ‘metabolic syndrome’.
Literatur
1.
Avogaro P, Crepaldi G, Enzi G, Tiengo A (1967) Associazione di iperlidemia, diabete mellito e obesita di medio grado. Acto Diabetol Lat 4:36–41CrossRef
2.
Haller H (1977) Epidemiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med 32:124–128PubMed
3.
Singer P (1977) Diagnosis of primary hyperlipoproteinemias. Z Gesamte Inn Med 32:129–133PubMed
4.
Himsworth H (1936) Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1:127–130CrossRef
5.
Shen S-W, Reaven GM, Farquhar JW (1970) Comparison of impedance to insulin mediated glucose uptake in normal and diabetic subjects. J Clin Invest 49:2151–2160PubMed
6.
Ginsburg H, Kimmerling G, Olefsky JM, Reaven GM (1975) Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest 55:454–461PubMed
7.
Reaven GM, Lerner R, Stern M, Farquhar JW (1967) Role of insulin in endogenous hypertriglyceridemia. J Clin Invest 46:1756–1767PubMed
8.
Olefsky JM, Farquhar JW, Reaven GM (1974) Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 57:551–560CrossRefPubMed
9.
Orchard TJ, Becker DJ, Bates M, Kuller LH, Drash AL (1983) Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol 118:326–337PubMed
10.
Olefsky JM, Kolterman OG, Scarlett JA (1982) Insulin action and resistance in obesity and non-insulin-dependent type II diabetes mellitus. Am J Physiol 243:E15–E30PubMed
11.
Stern MP, Haffner SM (1986) Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 6:123–130PubMed
12.
Modan M, Halkin H, Almog S et al (1985) Hyperinsulinemia: a link between hypertension, obesity, and glucose intolerance. J Clin Invest 75:809–817PubMed
13.
Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK (1988) Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism 37:338–345CrossRefPubMed
14.
Ferrannini E, Buzzigoli G, Bonadonna R et al (1987) Insulin resistance in essential hypertension. N Engl J Med 317:350–357PubMed
15.
Wingard DL, Barrett-Connor E, Criqui MH, Suarez L (1983) Clustering of heart disease risk factors in diabetic compared to non-diabetic adults. Am J Epidemiol 117:19–26PubMed
16.
Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607
17.
Zavaroni I, Bonora E, Pagliara M et al (1989) Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320:502–506PubMed
18.
Ferrannini E, Haffner SM, Mitchell BD, Stern MP (1991) Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34:416–422CrossRefPubMed
19.
Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP (1992) Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715–722PubMed
20.
Mykkanen L, Kuusisto J, Pyorala K, Laakso M (1993) Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia 36:553–559PubMed
21.
Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G A (1996) metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study. Diabetes Care 19:414–418PubMed
22.
Laakso M, Sarlund H, Mykkanen L (1990) Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223–231PubMed
23.
Schmidt MI, Watson RL, Duncan BB et al (1996) Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism 45:699–706CrossRefPubMed
24.
Meigs JB, D’Agostino RB, Wilson PWF, Cupples LA, Nathan DM, Singer DE (1997) Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46:1594–1600PubMed
25.
Liese AD , Mayer-Davis EJ, Haffner SM (1998) Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 20:157–172PubMed
26.
World Health Organization (1999) Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. World Health Organization, Geneva
27.
Expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497
28.
Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438CrossRefPubMed
29.
Balkau B, Charles MA, Drivsholm T et al (2002) Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. European Group for the Study of Insulin Resistance (EGIR). Diabetes Metab 28:364–376PubMed
30.
Einhorn D, Reaven GM, Cobin RH et al (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252PubMed
31.
Wilson PWF, Grundy SM (2003) The metabolic syndrome. Practical guide to origins and treatment: Part I. Circulation 108:1422–1425CrossRefPubMed
32.
Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA (2004) Clinical management of metabolic syndrome. Circulation 109:551–556CrossRefPubMed
33.
Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716CrossRefPubMed
34.
McNeill AM, Rosamond WD, Girman CJ et al (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28:385–390PubMed
35.
Stern SE, Williams K, Ferrannini E, Defronzo RA, Bogardus C, Stern MP (2005) Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54:333–339PubMed
36.
Ford ES, Giles WH (2003) A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26:575–581PubMed
37.
Meigs JB, Wilson PW, Nathan DM, D’Agostino RB Sr, Williams K, Haffner SM (2003) Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52:2160–2167PubMed
38.
Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J (1999) Insulin resistance syndrome predicts coronary heart disease events in elderly non-diabetic men. Circulation 100:123–128PubMed
39.
Kekalainen P, Sarlund H, Pyorala K, Laakso M (1999) Hyperinsulinemia cluster predicts the development of type 2 diabetes independent of a family history of diabetes. Diabetes Care 22:86–92PubMed
40.
Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K (2000) Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 20:538–544PubMed
41.
Kuusisto J, Lempiainen P, Mykkanen L, Laakso M (2001) Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care 24:1629–1633PubMed
42.
Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689PubMed
43.
Onat A, Ceyhan K, Basar O, Erer B, Tobrak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165:285–292CrossRefPubMed
44.
Alexander CM, Landsman PB, Teutsch SM, Haffner SM (2003) NCEP metabolic syndrome, diabetes mellitus and prevalence of coronary heart disease. Diabetes 52:1210–1214PubMed
45.
Katzmarzyk PT, Church TS, Blair SN (2004) Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164:1092–1097CrossRefPubMed
46.
Ford ES (2004) The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:309–314CrossRefPubMed
47.
Girman CJ, Rhodes T, Mercuri M et al (2004) The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93:136–141CrossRefPubMed
48.
Malik S, Wong ND, Franklin SS et al (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and on all causes in United States adults. Circulation 110:1245–1250CrossRefPubMed
49.
Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP (2004) National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251–1257CrossRefPubMed
50.
Scuteri A, Najjar S, Morrell C, Lakatta E (2005) The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events. Diabetes Care 28:882–887PubMed
51.
Bruno G, Merletti F, Biggeri A et al (2004) Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27:2689–2694PubMed
52.
Resnick HE, Jones K, Ruotolo G et al (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in non-diabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867PubMed
53.
Marroquin OC, Kip KE, Kelley DE et al (2004) Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women’s Ischemia Syndrome Evaluation. Circulation 109:714–721CrossRefPubMed
54.
Fuller JH , Shipley MJ, Rose G, Jarrett RJ, Keen H (1980) Coronary heart disease risk and impaired glucose tolerance: the Whitehall Study. Lancet 1:1373–1376PubMed
55.
Lippel K, Tyroler H, Eder H, Gotto A, Vahouny G (1981) Relationship of hypertriglyceridemia to atherosclerosis. Atherosclerosis 1:406–417
56.
Miller GJ, Miller NE (1975) Plasma high density lipoprotein concentration and development of ischemic heart disease. Lancet 1:16–19CrossRefPubMed
57.
Keys A, Aravanis C, Blackburn H et al (1972) Coronary heart disease: overweight and obesity as risk factors. Ann Intern Med 77:15–27PubMed
58.
Deckert T, Feldt-Rasmussen B, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 32:219–226CrossRefPubMed
59.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 360:1903–1913CrossRefPubMed
60.
Kannel WB, McGee DL (1979) Diabetes and cardiovascular risk factors in the Framingham study. Circulation 59:8–13PubMed
61.
Rosengren A, Welin L, Tsipigianni A, Wilhelmsen L (1989) Impact of cardiovascular risk factors on coronary heart disease and mortality among middle-aged diabetic men: a general population study. Br Med J 299:1127–1131
62.
Stamler J, Vaccaro O , Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444PubMed
63.
Ross R(1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126PubMed
64.
Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477–1482CrossRefPubMed
65.
Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843CrossRefPubMed
66.
Ridker PM (2003) Clinical applications of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363–369PubMed
67.
Ridker PM, Cannon CP, Morrow D et al (2005) C-reactive protein levels and outcomes after statin therapy. Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). N Engl J Med 352:20–28PubMed
68.
Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107:391–397CrossRefPubMed
69.
Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM (2003) C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 23:650–655CrossRefPubMed
70.
Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978PubMed
71.
McLaughlin T, Abbasi F, Lamendola C et al (2002) Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106:2908–2912CrossRefPubMed
72.
Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47PubMed
73.
Sattar N, Gaw A, Scherbakova O et al (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414–419CrossRefPubMed
74.
Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380–385CrossRefPubMed
75.
Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ (2004) Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110:803–809CrossRefPubMed
76.
Ridker PM, Wilson PW, Grundy SM (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818–2825CrossRefPubMed
77.
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214CrossRefPubMed
78.
Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830CrossRefPubMed
79.
Wellen KE, Hotamisligil GS (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785–1788CrossRefPubMed
80.
Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511PubMed
81.
Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556CrossRefPubMed
82.
Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935CrossRefPubMed
83.
Chandran M, Phillips SA, Ciaraldi T, Henry RR (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26:2442–2450PubMed
84.
Matsubara M, Maruoka S, Katayose S (2002) Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87:2764–2769CrossRefPubMed
85.
Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G (2002) Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 25:971–976PubMed
86.
Kumada M, Kihara S, Sumitsuji S et al (2003) Association of hypoadiponectinemia with coronary artery disease in men. Osaka CAD Study Group. Coronary artery disease. Arterioscler Thromb Vasc Biol 23:85–89CrossRefPubMed
87.
Kojima S, Funahashi T, Sakamoto T et al (2003) The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89:667–672CrossRefPubMed
88.
Zoccali C, Mallamaci F, Tripepi G et al (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141CrossRefPubMed
89.
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737PubMed
90.
Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE (1993) The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42:945–949CrossRefPubMed
91.
Haffner SM, D’Agostino R Jr, Mykkanen L et al (1999) Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:562–568PubMed
92.
Festa A, D’Agostino R Jr, Mykkanen L et al (1999) Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19:562–568PubMed
93.
Ernst E, Resch KL (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 18:956–963
94.
Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O (1998) Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care 21:649–654PubMed
95.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed
96.
Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM (2004) Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27:2676–2681 (‘Erratum’ in Diabetes Care 28:238, 2005)PubMed
97.
Klein BE, Klein R, Lee KE (2002) Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 25:1790–1794PubMed
98.
Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F (2002) Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 51:3069–3076PubMed
99.
Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). United Kingdom Prospective Diabetes Study (UKPDS) Group. Clin Sci 101:671–679CrossRefPubMed
100.
Stern MP, Williams K, Hunt KJ (2005) Impact on diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl 6:3–6CrossRef
101.
Yarnell JWG, Patterson CC, Bainton D, Sweetnam PM (1998) Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies. Heart 79:248–252PubMed
102.
Yeo WW, Yeo KR (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341–344CrossRefPubMed
103.
Song SH, Brown PM (2004) Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 21:238–245CrossRefPubMed
104.
McEwan P, Williams JE, Griffiths JD et al (2004) Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med 21:318–323CrossRefPubMed
105.
Pyorala K (1979) Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2:131–141PubMed
106.
Welborn TA, Wearne K (1979) Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2:154–160PubMed
107.
Fontbonne A, Charles MA, Thibult N et al (1991) Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 34:356–361CrossRefPubMed
108.
Moller LF, Jespersen J (1995) Fasting serum insulin levels and coronary heart disease in a Danish cohort: 17-year follow-up. J Cardiovasc Risk 2:235–240PubMed
109.
Perry IJ, Wannamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti KG (1996) Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol 144:224–234PubMed
110.
Despres JP, Lamarche B, Mauriege P et al (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952–957CrossRefPubMed
111.
Pyorala M, Miettinen H, Laakso M, Pyorala K (1998) Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 98:398–404PubMed
112.
Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G (1980) Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19:205–210CrossRefPubMed
113.
Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH (1997) A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 20:935–942PubMed
114.
Yip J, Facchini FS, Reaven GM (1998) Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83: 2773–2776CrossRefPubMed
115.
Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K (1990) 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects. Circulation 82:27–36PubMed
116.
Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K (2004) Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. DECODE Insulin Study. Diabetologia 47:1245–1256PubMed
117.
Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin K (1992) Hyperinsulinaemia is not a major coronary risk factor in elderly men. The study of men born in 1913. Diabetologia 35:766–770PubMed
118.
Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA (1994) Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol 4:40–45PubMed
119.
Ferrara A, Barrett-Connor EL, Edelstein SL (1994) Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984–1991. Am J Epidemiol 140:857–869PubMed
120.
Stern MP (1994) The insulin resistance syndrome: the controversy is dead, long live the controversy! Diabetologia 37:956–958PubMed
121.
Wingard DL, Barrett-Connor EL, Ferrara A (1995) Is insulin really a heart disease risk factor? Diabetes Care 18:1299–1304PubMed
122.
McKeigue P, Davey G (1995) Associations between insulin levels and cardiovascular disease are confounded by comorbidity. Diabetes Care 18:1294–1298PubMed
123.
Robbins DC, Andersen L, Bowsher R et al (1996) Report of the American Diabetes Association’s Task Force on standardization of the insulin assay. Diabetes 45:242–256PubMed
124.
Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495PubMed
125.
Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM (2000) Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy non-diabetic volunteers. Diabetes Care 23:171–175PubMed
126.
127.
Facchini FS, Hua N, Abbasi F, Reaven GM (2001) Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 86:3574–3578CrossRefPubMed
128.
Mykkanen L, Haffner SM, Ronnemaa T, Bergman RN, Laakso M (1997) Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. Am J Epidemiol 146:315–321PubMed
129.
Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE (2000) A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 49:2094–2101PubMed
130.
McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G (2003) Use of metabolic markers to identify overweight individuals who are insulin-resistant. Ann Intern Med 139:802–809PubMed
131.
Liao Y, Kwon S, Shaughnessy S et al (2004) Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27:978–983PubMed
132.
Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES (2004) Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53:1195–1200PubMed
133.
Laakso M, Sarlund H, Salonen R et al (1991) Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 11:1068–1076PubMed
134.
Agewall S, Fagerberg B, Attvall S, Wendelhag I, Urbanavicius V, Wikstrand J (1995) Carotid artery wall intima–media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 26:956–960PubMed
135.
Howard G, O’Leary DH, Zaccaro D et al (1996) Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93:1809–1817PubMed
136.
Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP (2000) Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101:975–980PubMed
137.
DeFronzo RA (1988) Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667–687PubMed
138.
Reaven GM (1995) Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473–486PubMed
139.
Mardia KV, Kent JT, Bibby JM (1979) Factor analysis. In: Mardia KV, Kent JT, Bibby JM (eds) Multivariate analysis. Academic, London pp 255–280
140.
Cureton EE, D’Agostino RB (1986) Factor analysis: an applied approach. Lawrence Erlbaum Associates, Hillsdale NJ
141.
Krzanowski WJ (1994) Explaining observed associations: latent-variable models. In: Krzanowski WJ (ed) Principles of multivariate statistical methods. A primer. Chapman and Hall, London, pp 93–106
142.
Lawlor DA, Ebrahim S, May M, Davey Smith G (2004) (Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol 159:1013–1018CrossRefPubMed
143.
Gray RS, Fabsitz RR, Cowan LD, Lee ET, Howard BV, Savage PJ (1998) Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. Am J Epidemiol 148:869–878PubMed
144.
Lehto S, Ronnemaa T, Pyorala K, Laakso M (2000) Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia 43:148–155CrossRefPubMed
145.
Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP (2000) Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152:897–907CrossRefPubMed
146.
Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ (2001) Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 24:1758–1763PubMed
147.
Hanley AJ, Karter AJ, Festa A et al (2002) Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the insulin resistance atherosclerosis study. Diabetes 51:2642–2647PubMed
148.
Wang JJ, Qiao Q, Miettinen ME, Lappalainen J, Hu G, Tuomilehto J (2004) The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a Chinese population with high postprandial glucose. Diabetes Care 27:2429–2437PubMed
149.
Ford ES (2003) Factor analysis and defining the metabolic syndrome. Ethn Dis 13:429–437PubMed
150.
Shen BJ, Todaro JF, Niaura R et al (2003) Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 157:701–711CrossRefPubMed
151.
Laws A, Reaven GM (1992) Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 231:25–30PubMed
152.
Carr DB, Utzschneider KM, Hull RL et al (2004) Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53:2087–2094PubMed
153.
Pyorala K, Ballantyne CM, Gumbiner B et al (2004) Reduction of cardiovascular events by simvastatin in non-diabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27:1735–1740PubMed
154.
UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854–865
155.
Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 346:393–403CrossRefPubMed
156.
Shadid S, Jensen MD (2003) Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26:3148–3152PubMed
157.
Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI (2001) Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Rosiglitazone Clinical Trials Study Group. J Clin Endocrinol Metab 86:280–288CrossRefPubMed
158.
Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group. Diabetes Care 23:1605–1611PubMed
159.
Freed MI, Ratner R, Marcovina SM et al (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Rosiglitazone study 108. Am J Cardiol 90:947–952CrossRefPubMed
160.
Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679–684CrossRefPubMed
161.
Satoh N, Ogawa Y, Usui T et al (2003) Anti-atherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493–2499PubMed
162.
Davidson MB (2003) Is treatment of insulin resistance beneficial independent of glycemia? Diabetes Care 26:3184–3186PubMed
163.
Chobanian AV, Bakris GL, Black HR et al (2003) Seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206–1252CrossRefPubMed
164.
Smith SC Jr, Jackson R, Pearson TA et al (2004) Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the world heart and stroke forum. Circulation 109:3112–3121CrossRefPubMed
165.
166.
Washington Post (2005) New diagnosis for overweight. Major risk factors add up to ‘metabolic syndrome’. Washington Post 8 February 2005: Sect. A, p1
167.
No authors listed (2000) Stedman’s medical dictionary, 27th edition. Lippincott, Williams and Wilkins, Baltimore, pp 1746
168.
American Diabetes Association (2005) Standards of medical care in diabetes. Diabetes Care 28:S4–S36
Metadaten
Titel
The metabolic syndrome: time for a critical appraisal
Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes
verfasst von
R. Kahn
J. Buse
E. Ferrannini
M. Stern
Publikationsdatum
01.09.2005
Erschienen in
Diabetologia / Ausgabe 9/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1876-2

Weitere Artikel der Ausgabe 9/2005

Diabetologia 9/2005 Zur Ausgabe

Article

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes

Editorial

The myth of the metabolic syndrome

Article

Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes

Research Letter

Immunological characteristics of diabetes in schizophrenia

Article

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

Article

Health-related quality of life of diabetic foot ulcer patients and their caregivers

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise